RT Journal Article
SR Electronic
T1 660 Phase 2 Study to evaluate the triplet combination of pemetrexed plus etrumadenant and zimberelimab in patients with previously treated advanced or MTAP-deficient metastatic urothelial carcinoma (mUC)
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A752
OP A752
DO 10.1136/jitc-2023-SITC2023.0660
VO 11
IS Suppl 1
A1 Alhalabi, Omar
A1 Sheth, Rahul
A1 Shah, Amishi
A1 Bathala, Tharekeswara
A1 Klimkowsky, Sergio P
A1 Qiao, Wei
A1 Chen, Jianfeng
A1 Yan, Xinmiao
A1 Goswami, Sangeeta
A1 Adriazola, Ana
A1 Siefker-Radtke, Arlene
A1 Campbell, Matthew
A1 Wang, Linghua
A1 Guo, Charles
A1 Gao, Jianjun
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A752.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.